Andrew Galazka

1.5k total citations
50 papers, 1.1k citations indexed

About

Andrew Galazka is a scholar working on Oncology, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Andrew Galazka has authored 50 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 16 papers in Pathology and Forensic Medicine and 15 papers in Immunology. Recurrent topics in Andrew Galazka's work include Multiple Sclerosis Research Studies (15 papers), Polyomavirus and related diseases (11 papers) and Chronic Lymphocytic Leukemia Research (10 papers). Andrew Galazka is often cited by papers focused on Multiple Sclerosis Research Studies (15 papers), Polyomavirus and related diseases (11 papers) and Chronic Lymphocytic Leukemia Research (10 papers). Andrew Galazka collaborates with scholars based in Germany, United States and Italy. Andrew Galazka's co-authors include Andrew Abdulahad, Axel Nolting, Gavin Giovannoni, Thomas Leist, Patrick Salmon, A. Darragh, Fernando Dangond, Stuart D. Cook, Christine Hicking and Xavier Montalbán and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Neurology and Cancer.

In The Last Decade

Andrew Galazka

47 papers receiving 1.0k citations

Peers

Countries citing papers authored by Andrew Galazka

Since Specialization

Citations

This map shows the geographic impact of Andrew Galazka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Galazka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Galazka more than expected).

Fields of papers citing papers by Andrew Galazka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Galazka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Galazka. The network helps show where Andrew Galazka may publish in the future.

Co-authorship network of co-authors of Andrew Galazka

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Galazka. A scholar is included among the top collaborators of Andrew Galazka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Galazka. Andrew Galazka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives 2024 ·Neurology and Therapy ·Mark S. Freedman, Patricia K. Coyle, Kerstin Hellwig, B. Singer, Daniel Wynn, Bianca Weinstock‐Guttman, Silva Markovic‐Plese, Andrew Galazka, Fernando Dangond, (unknown), Anthony T. Reder	4
2	146. Post-Approval Safety of Cladribine Tablets in the Treatment of Patients With Multiple Sclerosis: 2024 Update 2024 ·Multiple Sclerosis and Related Disorders ·Thomas Leist, (unknown), Danielle E. Harlow, Andrija Javor, Andrew Galazka, (unknown)	0
3	Post-Approval Safety of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis: 2023 Update 2023 ·Multiple Sclerosis and Related Disorders ·Gavin Giovannoni, Thomas Leist, Dominic Jack, Andrew Galazka, Nektaria Alexandri, Axel Nolting	0
4	Updated Post-Approval Safety of Cladribine Tablets in the Treatment of Multiple Sclerosis, With Particular Reference to Respiratory Viral Infections and COVID-19 (1927) 2021 ·Neurology ·Gavin Giovannoni, Jeffrey S. Berger, Thomas Leist, Dominic Jack, Andrew Galazka, Axel Nolting, (unknown)	0
5	Review of Transporter Substrate, Inhibitor, and Inducer Characteristics of Cladribine 2021 ·Clinical Pharmacokinetics ·Róbert Hermann, Péter Krajcsi, Markus Fluck, (unknown), (unknown), Andrew Galazka, Alain Munafo	6
6	COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update 2021 ·Multiple Sclerosis and Related Disorders ·Dominic Jack, Doris Damian, Axel Nolting, Andrew Galazka	19
7	Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study 2020 ·Multiple Sclerosis and Related Disorders ·Bruce Cree, James D. Bowen, Hans‐Peter Hartung, Patrick Vermersch, (unknown), Doris Damian, Yann Hyvert, Fernando Dangond, Andrew Galazka, Megan Grosso, Daniel L. Jones, Thomas Leist	8
8	Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis 2020 ·Multiple Sclerosis and Related Disorders ·Thomas Leist, S. D. Cook, Gıancarlo Comı, Xavier Montalbán, Gavin Giovannoni, Axel Nolting, Doris Damian, S. Syed, Andrew Galazka	43
9	The multiple sclerosis PRISMS study: Prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis 1997 ·Oxford University Research Archive (ORA) (University of Oxford) ·George C. Ebers, (unknown), D. W. Paty, (unknown), Mark S. Freedman, Hans‐Peter Hartung, (unknown), (unknown), (unknown), J. Wikström, H. Carton, (unknown), (unknown), Robert Medaer, L. D. Blumhardt, David Barnes, (unknown), Michel Chofflon, (unknown), (unknown), John Newsom–Davis, (unknown), (unknown), (unknown), (unknown), Florent Dupont, Andrew Galazka, Robert Hyde, (unknown), Andrew Abdulahad	2
10	Recombinant human interferon- in the treatment of condylomata acuminata 1997 ·International Journal of STD & AIDS ·W W Dinsmore, (unknown), (unknown), J R Harris, A McMillan, (unknown), Patrick Engrand, (unknown), Andrew Galazka, Andrew Abdulahad, (unknown)	13
11	Clinical assessment of human gonadotrophins produced by recombinant DNA technology 1996 ·Human Reproduction ·Ernest Loumaye, Isabelle Martineau, (unknown), Louis O’Dea, Susan Ince, Colin M. Howles, (unknown), Katherine Van Loon, Andrew Galazka	43
12	Pharmacokinetics and Pharmacodynamics of Recombinant Human Interferon-β in Healthy Male Volunteers 1996 ·Journal of Interferon & Cytokine Research ·Patrick Salmon, (unknown), Andrew Galazka, Andrew Abdulahad, A. Darragh	145
13	Repetitive Weekly Cycles of 4-Day Continuous Infusion of Recombinant Interleukin-2: A Phase I Study 1992 ·Journal of Immunotherapy ·(unknown), Rob L. H. Jansen, P.H.M. de Mulder, D. Batchelor, Andrew Galazka, R. L. H. Bolhuis, G. Stoter	6
14	Phase I study of subcutaneously-administered bacterially-synthesised recombinant human granulocyte-macrophage colony-stimulating factor 1992 ·European Journal of Cancer ·Gary K. Schwartz, Deborah Lehrer, (unknown), James F. Holland, J. Mandeli, Jeffrey J. Collins, Andrew Galazka, (unknown)	8
15	Combination of GM-CSF and Cytosine in Myelodysplasia Results in Improved Neutrophil Function 1992 ·Acta Haematologica ·D. W. Galvani, Yushe Dang, Fiona L. Watson, (unknown), Andrew Galazka, Richard D. Weiner, John Davies, John C. Cawley	5
16	The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2 1991 ·British Journal of Cancer ·Robert C. Stein, Vera Malkovska, (unknown), Andrew Galazka, (unknown), (unknown), R. J. SHEARER, R.A. Marsden, David Bevan, (unknown), R. Charles Coombes	56
17	Malignant plasma cells are sensitive to LAK cell lysis: pre‐clinical and clinical studies of interleukin 2 in the treatment of multiple myeloma 1990 ·British Journal of Haematology ·David Gottlieb, H. G. Prentice, Atul Mehta, Andrew Galazka, H E Heslop, A. V. Hoffbrand, Malcolm K. Brenner	27
18	Evaluation of the effect of continuous infusion recombinant interleukin-2 (bioleukin) on peripheral blood leucocytes of patients with terminal malignancy 1989 ·British Journal of Cancer ·R.T.D. Oliver, David L. Crosby, A.M.E. Nouri, Elizabeth Scott, Andrew Galazka	6
19	In vivo activation of lymphocytes in melanoma patients receiving escalating doses of recombinant interleukin 2 1988 ·International Journal of Cancer ·Carlo Gambacorti‐Passerini, Marina Radrizzani, Raffaele Marolda, Filiberto Belli, G Sciorelli, Andrew Galazka, John Schindler, Natale Cascinelli, Giorgio Parmiani	26
20	Small cell lung carcinoma. A phase II evaluation of r-interferon-γ 1987 ·Cancer ·H Newman, Norman M. Bleehen, Andrew Galazka, (unknown)	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact